Brii Biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice.
Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline.
Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.
Company Details
- Employees
- 84
- Address
- 110 N Corcoran St, Suite 05-110
- BD****@****bio.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- briibio.com
- Keywords
- Biotechnology.
- HQ
- Durham, North Carolina
Brii Biosciences Questions
Brii Biosciences's website is briibio.com
Brii Biosciences's LinkedIn profile is https://www.linkedin.com/company/brii-biosciences
Brii Biosciences has
84 employees.
View email and phone details for 84
employees at Brii Biosciences.
Brii Biosciences's industry is
Biotechnology Research
Brii Biosciences's top competitors are
Legend Biotech,
Precision Biosciences, Inc.,
Tune Therapeutics,
Kriya Therapeutics, Inc.,
Assembly Biosciences, Inc.,
Bluejay Therapeutics,
Lykos Therapeutics,
Vera Therapeutics, Inc.,
Vir Biotechnology, Inc.,
Cybin Inc.
Brii Biosciences's support email address is BD@briibio.com
Brii Biosciences's categories are Biotechnology Research
